100 related articles for article (PubMed ID: 19952302)
1. Redefining treatment success in type 2 diabetes mellitus: Comprehensive targeting of core defects.
Cefalu WT; Richards RJ; Melendez-Ramirez LY
Cleve Clin J Med; 2009 Dec; 76 Suppl 5():S39-47. PubMed ID: 19952302
[TBL] [Abstract][Full Text] [Related]
2. Current antihyperglycemic treatment strategies for patients with type 2 diabetes mellitus.
Blonde L
Cleve Clin J Med; 2009 Dec; 76 Suppl 5():S4-11. PubMed ID: 19952303
[TBL] [Abstract][Full Text] [Related]
3. Patient and treatment perspectives: Revisiting the link between type 2 diabetes, weight gain, and cardiovascular risk.
Peters AL
Cleve Clin J Med; 2009 Dec; 76 Suppl 5():S20-7. PubMed ID: 19952300
[TBL] [Abstract][Full Text] [Related]
4. Diabetes and obesity: therapeutic targeting and risk reduction - a complex interplay.
Niswender K
Diabetes Obes Metab; 2010 Apr; 12(4):267-87. PubMed ID: 20380648
[TBL] [Abstract][Full Text] [Related]
5. Advances in the treatment of type 2 diabetes mellitus.
Israili ZH
Am J Ther; 2011; 18(2):117-52. PubMed ID: 19834322
[TBL] [Abstract][Full Text] [Related]
6. The effects of pharmacologic agents for type 2 diabetes mellitus on body weight.
Pi-Sunyer FX
Postgrad Med; 2008 Jul; 120(2):5-17. PubMed ID: 18654064
[TBL] [Abstract][Full Text] [Related]
7. Beyond glycemic control: treating the entire type 2 diabetes disorder.
Brunton S
Postgrad Med; 2009 Sep; 121(5):68-81. PubMed ID: 19820276
[TBL] [Abstract][Full Text] [Related]
8. Incretin therapy for type 2 diabetes mellitus.
Klonoff DC
Adv Ther; 2010 Dec; 27(12):881-94. PubMed ID: 20978879
[TBL] [Abstract][Full Text] [Related]
9. Cardiovascular implications of antihyperglycemic therapies for type 2 diabetes.
Ovalle F
Clin Ther; 2011 Apr; 33(4):393-407. PubMed ID: 21635987
[TBL] [Abstract][Full Text] [Related]
10. Rationale for dipeptidyl peptidase 4 inhibitors: a new class of oral agents for the treatment of type 2 diabetes mellitus.
Campbell RK
Ann Pharmacother; 2007 Jan; 41(1):51-60. PubMed ID: 17190843
[TBL] [Abstract][Full Text] [Related]
11. Improving glucagon-like peptide-1 dynamics in patients with type 2 diabetes mellitus.
Freeman JS
J Am Osteopath Assoc; 2012 Jan; 112(1 Suppl 1):S2-6. PubMed ID: 22267300
[TBL] [Abstract][Full Text] [Related]
12. Incretin mimetics and dipeptidyl peptidase-IV inhibitors: potential new therapies for type 2 diabetes mellitus.
Triplitt C; Wright A; Chiquette E
Pharmacotherapy; 2006 Mar; 26(3):360-74. PubMed ID: 16503716
[TBL] [Abstract][Full Text] [Related]
13. Fate of the beta-cell in the pathophysiology of type 2 diabetes.
Campbell RK
J Am Pharm Assoc (2003); 2009; 49 Suppl 1():S10-5. PubMed ID: 19801360
[TBL] [Abstract][Full Text] [Related]
14. Beyond insulin replacement: addressing the additional needs of the diabetes patient.
Dailey G
Diabetes Obes Metab; 2008 Jul; 10 Suppl 2():83-97. PubMed ID: 18577160
[TBL] [Abstract][Full Text] [Related]
15. How to implement incretin therapy.
Cobble ME
J Fam Pract; 2008 Sep; 57(9 Suppl):S26-31. PubMed ID: 18786341
[TBL] [Abstract][Full Text] [Related]
16. Achieving glycemic control: cornerstone in the treatment of patients with multiple metabolic risk factors.
Spellman CW
J Am Osteopath Assoc; 2009 May; 109(5 Suppl):S8-S13. PubMed ID: 19451256
[TBL] [Abstract][Full Text] [Related]
17. Cardiovascular manifestations of insulin resistance.
Chahwala V; Arora R
Am J Ther; 2009; 16(5):e14-28. PubMed ID: 19114874
[TBL] [Abstract][Full Text] [Related]
18. Beyond glycemic control: the effects of incretin hormones in type 2 diabetes.
Martin CL
Diabetes Educ; 2008; 34 Suppl 3():66S-72S. PubMed ID: 18525067
[TBL] [Abstract][Full Text] [Related]
19. Future perspectives on glucagon-like peptide-1, diabetes and cardiovascular risk.
Mannucci E; Rotella CM
Nutr Metab Cardiovasc Dis; 2008 Nov; 18(9):639-45. PubMed ID: 18849155
[TBL] [Abstract][Full Text] [Related]
20. Newly approved and promising antidiabetic agents.
Combettes M; Kargar C
Therapie; 2007; 62(4):293-310. PubMed ID: 17983555
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
